Ask a Question

You visited our site and still have questions? Feel free to contact us

Consultation and guidance given not in the framework of service does not serve as a replacement for a physician’s examination or consultation, and is not considered a “medical diagnosis” or “medical opinion". In all cases of urgency, distress or emergency (physical and/or mental), seek medical care with a family doctor, closest emergency room, and/or ambulatory service.   

Contact Us


Terms of use

Medix FTP Service (the "Service") is designed to provide you with an easy way to transfer files relevant to the management of your case to Medix Medical Services Europe Limited ("Medix", "we" and "us").


The following terms and conditions together with the Medix Information Security Policy (which may be found at http://medix- (together, the "Terms of Service"), form the agreement between you and us in relation to your use of the Service. You should read the Terms of Service carefully before agreeing to them. If you do not understand any part of the Terms of Services, then please contact us at for further information. You acknowledge and agree that by clicking on the "Upload" button, you are indicating that you accept the Terms of Services and agree to be bound by them.


Using the Service


In order to use the Service, you will be required to log in by submitting your member number which was provided to you by the Medix staff, your name and e-mail address. Once you have logged in, you will be able to upload files to the Service. We will download your files to our system and no copy will be retained on the server used to provide the Service. For detailed upload instructions, please click here.


Protection of your information


We take the safeguarding of your information very seriously. In order to prevent unauthorised access or disclosure of your information we have put in place appropriate physical, electronic and administrative procedures to safeguard and secure the files you upload to the Service. However, no method of transmission over the internet, or method of electronic data storage is 100% secure and while we have put in place appropriate protections, we cannot guarantee the security of information you upload to the Service.


Quality and availability of the Service


While we make reasonable efforts to provide the Service, it is provided "as is" with no representation, guarantee or warranty of any kind as to its availability, functionality, that it will meet your requirements or that it will be free of errors or viruses.


We will not be responsible for any damage to your computer system or the computer system of any third party resulting from your use of the Services where such damage is caused by circumstances which are beyond our reasonable control.


I agree
Contact Us
Contact Us

For the First Time in 30 Years, a New Drug for Metastatic Bladder Cancer

By: Dr. A. Peer

Immunotherapy, the revolutionary treatment that harnesses the immune system against cancer supplies another breakthrough

Treatments of metastatic Bladder cancer have been stagnant for over 3 decades.
Over 10,000 patients are diagnosed with this malignancy annually, most of which are earlier stage. In these cases, surgery, a special method of chemotherapy and radiotherapy are available. 15% however are diagnosed with advanced, spread disease which is more difficult to treat. Chemotherapy is the only option for metastatic bladder cancer, with only one line of treatment being offered. This means that if the initial chemotherapy doesn't work, there are no alternatives.
This is why the recent breakthrough is so exciting. Immunotherapy has been celebrated as the latest and greatest in oncology since 2013, when the acclaimed journal Science declared it to be the breakthrough of the year. Ever since, it has supplied cutting edge drugs for skin, lung, renal and uterine cancer. Now, the same underlying method has been successfully applied to bladder cancer. 
Atezolizumab or Tecentriq is the name of the new drug that was recently approved for use by the FDA. Authorization followed publication of a study which showed serious advantages. The study followed 310 metastatic cancer patients that were treated with the new drug. Results were overwhelming; almost double the overall survival rates after a year of treatment compared with chemotherapy. Most patients treated continued to have positive responses at two year follow ups. 
Although Tecentriq is the first immunotherapy drug authorized for Bladder cancer, a number of others are currently being studied. Leading pharma companies are rushing to get FDA approval so they can get their drugs into the market. For many this is good news, making the prospects of late stage bladder cancer a little bit brighter. 

By continuing to use this site you consent to the use of cookies on your device as described in our cookie policy unless you have disabled them. You can change your cookie settings at any time but parts of our site will not function correctly without them.